PipelineReview.com7h
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
DUBLIN, Ireland I December 19, 2024 I Prothena Corporation plc (NASDAQ:PRTA), today announced results from the Phase IIb PADOVA study conducted by partner Roche investigating prasinezumab in 586 ...
PipelineReview.com6h
Ottimo Pharma Raises over $140 Million in Series A Financing
LONDON, UK and BOSTON, MA, USA I December 19, 2024 I Ottimo Pharma (“Ottimo”), a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, today ...
PipelineReview.com9h
Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
RAHWAY, NJ, USA I 18, 2024 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical ...
PipelineReview.com9h
FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
MIAMI, FL, USA I 18, 2024 I Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug ...
PipelineReview.com7h
BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program
STOCKHOLM, Sweden I December 19, 2024 I BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol Myers Squibb (NYSE: ...
PipelineReview.com7h
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
NEW YORK, NY, USA I December 18, 2024 I Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the Food and Drug ...
PipelineReview.com9h
Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical
SYDNEY, Australia I 18, 2024 I Clarity Pharmaceuticals(ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a ...
PipelineReview.com2d
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
PARIS, France and Parsippany, NJ, USA I December 17, 2024 I Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today ...
PipelineReview.com2d
Aflibercept 8 mg met primary endpoint in phase III study and demonstrates vision gains with extended treatment intervals in retinal vein occlusion
Approximately 90% of aflibercept 8 mg patients were extended to every 8-week dosing and maintained their interval through 36 weeks ...
PipelineReview.com2d
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with ...
PipelineReview.com2d
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer
CHICAGO, IL and FORT WORTH, TX, USA I 17, 2024 I Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...
PipelineReview.com2d
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in ...